{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-24-018350","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2024-12-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.245233+00:00","generated_at":"2026-05-28T23:15:41.682282+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Precigen sells FCX-007 assets for $8.5M cash, exits Castle Creek collaboration","bullets":["Asset Acquisition Agreement with Innovator 21 (Paragon affiliate) closed Dec 24, 2024 for $8.5M cash.","Sold IP and royalty rights related to FCX-007, a clinical-stage candidate for Epidermolysis Bullosa.","Precigen has no further rights or obligations to Castle Creek or retained product royalties.","Proceeds to be used for working capital and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-24-018350","json":"https://secwatch.observer/filing/0000950103-24-018350.json","markdown":"https://secwatch.observer/filing/0000950103-24-018350.md","text":"https://secwatch.observer/filing/0000950103-24-018350.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324018350/0000950103-24-018350-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324018350/dp222589_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:15:41.682282+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}